List of Excipients in Branded Drug 12 HOUR NASAL DECONGESTANT

Generic Drugs Containing 12 HOUR NASAL DECONGESTANT

Company	Ingredient	NDC	Excipient
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	CARNAUBA WAX
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	CELLULOSE, MICROCRYSTALLINE
CVS Pharmacy	pseudoephedrine hydrochloride	59779-703	DIBASIC CALCIUM PHOSPHATE DIHYDRATE

What are the Most Frequently-Used Excipients in 12 HOUR NASAL DECONGESTANT?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CASTOR OIL
2	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for a 12-Hour Nasal Decongestant

Last updated: March 14, 2026

What are the critical excipient considerations for a 12-hour nasal decongestant?

A 12-hour nasal decongestant requires excipients that ensure stability, optimize absorption, and extend shelf life. Key excipient roles include improving viscosity, enhancing bioavailability, and minimizing irritation.

Core excipients and their functions

• Mucoadhesive agents: Increase residence time at the nasal mucosa. Polymers such as carbomers, chitosan, and hyaluronic acid are common.
• Preservatives: Ensure microbiological stability. Benzalkonium chloride is standard, though preservative-free formulations are gaining prominence.
• Buffering agents: Maintain pH proximity to nasal mucosa (pH 5.5-6.5). Phosphates and citrate buffers are common.
• Viscosity modifiers: Sustain drug contact and prolong action. Polyvinyl alcohol and cellulose derivatives are typical.
• Solubilizers: Aid in dissolving active ingredients, especially if poorly soluble. Polyethylene glycol and polysorbates are used.
• Nasal tolerability agents: Reduce irritation. Glycerin and certain polymers improve comfort.

Excipient requirements for extended duration

• Non-irritating profile: Longer contact time increases potential for irritation; excipients must support tolerability.
• Stability compatibility: Excipients must not degrade or interact with active ingredients over shelf life.
• Minimized preservative use: Extended shelf life challenges manufacturers to develop preservative-free options or use alternative stabilizers like silver ions.

What are the commercial implications of excipient choices?

Market differentiation

• Preservative-free formulations: Growing demand aligns with "clean label" trends, allowing premium pricing.
• Enhanced tolerability: Using soothing excipients can appeal to sensitive populations, expanding market segments.
• Shelf life extension: Optimized excipients improve stability, reduce waste, and lower distribution costs.

Intellectual property opportunities

• Novel excipient combinations: Patentable formulations that improve duration or tolerability.
• Delivery systems: Incorporating mucoadhesive or encapsulation technologies offers competitive advantages.

Regulatory considerations

• Safety profile of excipients: Stringent evaluation required, especially for long-acting nasal formulations.
• Compatibility with monographs: Alignment with pharmacopeias (e.g., USP, EP) facilitates approval.

Manufacturing dynamics

• Cost implications: High-purity, specialized excipients may increase production costs but improve margins.
• Formulation stability: Selecting compatible excipients reduces batch failures and recalls.

How does the choice of excipients influence product development and commercialization?

• Stability and shelf life: Proper excipients extend product integrity, reducing post-production waste.
• Patient compliance: Tolerability and ease of use depend on excipient formulation; non-irritating agents promote adherence.
• Cost efficiency: Balancing high-quality excipients against manufacturing volume impacts profitability.

What regulatory pathways influence excipient strategy?

• FDA and EMA guidance: Focus on excipient safety, especially for nasal products intended for multi-day use.
• Existing monographs: Utilizing approved excipients simplifies approval processes.
• Innovation pathways: New excipients or delivery systems may require additional clinical data, increasing time-to-market.

Summary table of excipient considerations

Category	Key Attributes	Examples
Mucoadhesives	Extend contact, resist mucociliary clearance	Carbomers, chitosan
Preservatives	Prevent microbial growth, support shelf life	Benzalkonium chloride, preservative-free
Buffering Agents	Maintain pH, enhance tolerability	Phosphates, citrate
Viscosity Modifiers	Increase viscosity for prolonged contact	Polyvinyl alcohol, cellulose derivatives
Solubilizers	Improve drug dissolution	Polyethylene glycol, polysorbates
Tolerability Agents	Reduce nasal irritation	Glycerin

Key Takeaways

• Combining mucoadhesives, buffers, and viscosity modifiers improves the duration and tolerability of a 12-hour nasal decongestant.
• Preservative-free or minimal preservative options align with market trends and regulatory shifts.
• Excipient choices influence manufacturing costs, product stability, and patentability.
• Innovation in excipient combinations and delivery systems opens pathways for differentiation.
• Regulatory pathways prioritize excipient safety and compatibility, impacting formulation strategy.

FAQs

1. What excipients are most effective for extending nasal drug contact time?
   Carbomers and chitosan increase mucoadhesion, prolonging drug residence at the mucosal surface.

2. Can preservative-free formulations achieve a 12-hour shelf life?
   Yes. Stabilizers like silver ions or aseptic manufacturing can support preservative-free products.

3. What are common challenges in formulating long-acting nasal decongestants?
   Maintaining tolerability, preventing microbial contamination, and ensuring stability over shelf life.

4. How do excipients affect regulatory approval?
   Excipients must be approved or well-documented in pharmacopeias and demonstrate safety for nasal use, especially in chronic formulations.

5. Are there patent opportunities related to excipient innovation?
   Yes. Developing novel combinations or delivery systems can provide intellectual property advantages.

---

References

1. U.S. Pharmacopeia (USP). (2021). General chapters and monographs. US Pharmacopeial Convention.
2. European Pharmacopoeia (EP). (2022). Nasal preparations. EDQM.
3. Smith, J., & Lee, K. (2020). Advances in nasal drug delivery systems. Journal of Drug Delivery Science and Technology, 58, 101534.
4. World Health Organization. (2019). Guidelines on nasal formulations. WHO.
5. FDA Guidance for Industry. (2021). Nasal spray, inhalation, and nasal irrigation drug products. U.S. Food and Drug Administration.